Vukmir & Associates, working with Covington & Burling and Gibson, Dunn & Crutcher, has advised on Croatian aspects of the spinoff of Merck’s women’s health business, now operating under the name Organon. Baker McKenzie reportedly advised Merck as well.
According to Merck’s official announcement on the completion of the project, Merck’s goal with the spinoff was to create two patient-focused companies with an enhanced strategic and operational focus, improved agility, simplified operating models, optimized capital structures, and improved financial profiles. Merck believes the transaction will deliver significant benefits for both Merck and Organon and create value for Merck shareholders. The spinoff is expected to allow Merck to increase its focus on key growth pillars, achieve higher revenue and EPS growth rates, and enable incremental operating efficiencies of approximately USD 1.5 billion.
Vukmir & Associates’ team was led by Partner Tomislav Pedisic and included Associates Tea Cerinski and Hrvoje Klisanic.
